跳至主要内容
临床试验/EUCTR2013-003707-18-NL
EUCTR2013-003707-18-NL进行中(未招募)不适用

Absorption of sublingual delivered fentanyl (Abstral®) in head and neck cancer patients treated with curatively aimed chemo-radiotherapy - Absorption of fentanyl

未提供0 个研究点目标入组 13 人开始时间: 2013年12月18日最近更新:
适应症
相关药物

试验速览

阶段
不适用
状态
进行中(未招募)
入组人数
13

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

性别
All

入选标准

  • - patients with head and neck cancer and planned treatment with chemo-radiotherapy
  • - written informed consent
  • - age > or = 18
  • - no serious psychiatric illness, confusion or intellectual disability
  • Are the trial subjects under 18? no
  • Number of subjects for this age range:
  • F.1.2 Adults (18-64 years) yes
  • F.1.2.1 Number of subjects for this age range 13
  • F.1.3 Elderly (>=65 years) no
  • F.1.3.1 Number of subjects for this age range

排除标准

  • - use of fentanyl medication within one week before inclusion in the study (other opioid and non-opioid analgesics are allowed)
  • - opioid intolerance
  • - former allergic reactions to opioids
  • - the use of cytochrome P450 (CYP) inhibitors or inducers is not an exclusion criterion by itself. However, the patient should not change its use during the sampling periods, to exlude altered CYP function on the PK of Abstral

研究者

发起方
未提供

相似试验